Showing 241 - 260 results of 368 for search '"Shen (Chinese ', query time: 0.09s Refine Results
  1. 241
  2. 242
  3. 243
  4. 244

    Poor Glycemic Control in Carbapenem-Resistant Klebsiella pneumoniae Infections: Impact on Epidemiological Features, Mortality Risks, and Polymyxin Resistance by Wang Q, Yan T, Ma C, Teng X, Shen C, Wang N, Yu K, Chu W, Zhou Q, Liu Z

    Published 2025-02-01
    “…Qiuyan Wang,1 Tao Yan,1 Chengcheng Ma,1 Xuan Teng,1 Chengyin Shen,2 Na Wang,3 Kexue Yu,1 Wenwen Chu,1 Qiang Zhou,1 Zhou Liu1,4 1Department of Clinical Laboratory, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, People’s Republic of China; 2Anhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui, People’s Republic of China; 3Institute of Health Sciences and Technology, Institutes of Physical and Information Technology, Anhui University, Hefei, Anhui, People’s Republic of China; 4Department of Clinical Laboratory Center, Anhui Chest Hospital, Hefei, Anhui, People’s Republic of ChinaCorrespondence: Zhou Liu, Email liuzhou0112@ahmu.edu.cnPurpose: This study aims to investigate the relationship between glycemic control and epidemiological characteristics of patients infected with carbapenem-resistant Klebsiella pneumoniae (CRKP), to identify mortality risk factors associated with CRKP infection, and to evaluate the impact of glucose on the resistance of CRKP to polymyxin and serum killing.Patients and Methods: Clinical cases of 218 patients infected with CRKP were collected from a large tertiary public hospital in Anhui Province. …”
    Get full text
    Article
  5. 245
  6. 246
  7. 247
  8. 248
  9. 249
  10. 250
  11. 251
  12. 252
  13. 253
  14. 254
  15. 255
  16. 256

    Co-Delivery of Dacarbazine and miRNA 34a Combinations to Synergistically Improve Malignant Melanoma Treatments by Ding B, Li M, Zhang J, Zhang X, Gao H, Gao J, Shen C, Zhou Y, Li F, Liu A

    Published 2025-01-01
    “…Baoyue Ding,1,2,* Mingjuan Li,2,* Jie Zhang,2,* Xiaojuan Zhang,2 Huan Gao,2 Jianqing Gao,3 Chunyan Shen,4 Yan Zhou,4 Fanzhu Li,5 Ailin Liu1 1Department of Pharmaceutical Analysis, Higher Educational Key Laboratory for Nano Biomedical Technology of Fujian Province, The School of Pharmacy, Fujian Medical University, Fuzhou, 350122, People’s Republic of China; 2Jiaxing Key Laboratory for Photonanomedicine and Experimental Therapeutics, Department of Pharmaceutics, Jiaxing University College of Medicine, Jiaxing, Zhejiang, People’s Republic of China; 3Institute of Pharmaceutics, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, Zhejiang, 310058 People’s Republic of China; 4Jiaxing Institute for Food, Drug and Product Quality Control, Jiaxing, Zhejiang, People’s Republic of China; 5Zhejiang Chinese Medical University, School of Pharmaceutical Science, Hangzhou, 310053, People’s Republic of China*These authors contributed equally to this workCorrespondence: Fanzhu Li; Ailin Liu, Email lifanzhu@zcmu.edu.cn; ailinliu@mail.fjmu.edu.cnPurpose: The incidence of malignant melanoma (MM) has risen over the past three decades, and despite advancements in treatment, there is still a need to improve treatment modalities. …”
    Get full text
    Article
  17. 257
  18. 258
  19. 259
  20. 260